These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23977244)

  • 41. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
    Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
    Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
    Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
    Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
    Leung W; Kvizhinadze G; Nair N; Blakely T
    PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Breast cancer subtypes based on ER/PR and Her2 expression: comparison of MR imaging features].
    Hao L; Yu RS; Cui F; Ren XC; Xu HB; Xu KY
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(11):819-23. PubMed ID: 23859386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
    Thompson AM; Jordan LB; Quinlan P; Anderson E; Skene A; Dewar JA; Purdie CA;
    Breast Cancer Res; 2010; 12(6):R92. PubMed ID: 21059212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
    Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
    Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Cancer Causes Control; 2011 Mar; 22(3):399-405. PubMed ID: 21184265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast feeding, parity and breast cancer subtypes in a Spanish cohort.
    Redondo CM; Gago-Domínguez M; Ponte SM; Castelo ME; Jiang X; García AA; Fernández MP; Tomé MA; Fraga M; Gude F; Martínez ME; Garzón VM; Carracedo Á; Castelao JE
    PLoS One; 2012; 7(7):e40543. PubMed ID: 22792365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Hwang KT; Kim EK; Jung SH; Lee ES; Kim SI; Lee S; Park HK; Kim J; Oh S; Kim YA;
    Breast Cancer Res Treat; 2018 Jun; 169(2):311-322. PubMed ID: 29383628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.